Erratum: Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (acosog z4051) (Annals of Oncology (2014) 25 (1039-1044) DOI: 10.1093/annonc/mdu091)

A. C. Lockhart, C. E. Reed, P. A. Decker, B. F. Meyers, M. K. Ferguson, A. R. Oeltjen, J. B. Putnam, S. D. Cassiv, A. J. Montero, T. E. Schefter

Research output: Contribution to journalComment/debate

Abstract

The following funding statement was missing from the original manuscript: Supported by NIH grants U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology. This has now been amended in the online version.

Original languageEnglish (US)
Pages (from-to)345
Number of pages1
JournalAnnals of Oncology
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Erratum: Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (acosog z4051) (Annals of Oncology (2014) 25 (1039-1044) DOI: 10.1093/annonc/mdu091)'. Together they form a unique fingerprint.

  • Cite this